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Abstract
The cortical actin cytoskeleton beneath the plasma membrane represents a physical barrier that vaccinia virus has to
overcome during its exit from an infected cell. Previous observations using overexpression and pharmacological approaches
suggest that vaccinia enhances its release by modulating the cortical actin cytoskeleton by inhibiting RhoA signalling using
the viral protein F11. We have now examined the role of F11 and its ability to interact with RhoA to inhibit its downstream
signalling in the spread of vaccinia infection both in vitro and in vivo. Live cell imaging over 48 hours reveals that loss of F11
or its ability to bind RhoA dramatically reduces the rate of cell-to-cell spread of the virus in a cell monolayer. Cells infected
with the DF11L virus also maintained their cell-to-cell contacts, and did not undergo virus-induced motility as observed
during wild-type infections. The DF11L virus is also attenuated in intranasal mouse models of infection, as it is impaired in its
ability to spread from the initial sites of infection to the lungs and spleen. Loss of the ability of F11 to bind RhoA also
reduces viral spread in vivo. Our results clearly establish that viral-mediated inibition of RhoA signalling can enhance the
spread of infection not only in cell monolayers, but also in vivo.
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Introduction
Vaccinia virus, the prototypic and most characterized member of
theorthopoxvirusgenusofthe poxvirdaeisa largedoublestranded DNA
virus that replicates in the cytoplasm of its infected host cell [1,2,3].
Replication and viral particle assembly, which involves a complex
series events that are still not fully understood, occurs within viral
factories localized at or near the microtubule-organizing center of
the cell [1,2,3]. Replication initially results in the formation of
intracellular mature virions (IMV) around 5–6 hours post infection,
although this can vary depending on the cell type. IMV are
infectious but are principally only released from the infected cells
when they undergo lysis. During the vaccinia infection cycle a
proportion of IMV can also become wrapped by a membrane
cisternae derived from the Trans-Golgi network or endosomal
compartments that contain a subset of integral viral membrane
proteins [3,4]. This envelopment results in the formation of intra-
cellular enveloped virions (IEV), which are capable of undergoing
kinesin-1 dependent microtubule transport from their peri-nuclear
site of assembly to the cell periphery [5,6,7,8,9,10].
Upon reaching the cell periphery IEV switch transport systems
and undergo actin-dependent movements in the cell cortex [11].
These viral movements, which have an average speed of
0.35 mm sec
21, are suggestive of a myosin dependent transport
step through the cortical actin prior to fusion with the plasma
membrane [11]. Fusion of the IEV with the plasma membrane
results in the formation of the extra-cellular virions, a large
proportion of which, remain associated with the outside of the cell
[3,4]. These cell associated virus particles are able to locally
activate Src and Abl family kinases to induce phosphorylation of
an integral IEV membrane protein A36 [12,13,14,15], which is
localized in the plasma membrane beneath the virus particle
[4,16,17]. Phosphorylation of A36 leads to the recruitment of a
signalling complex, consisting of Grb2, Nck, WIP (WASP
interacting protein) and N-WASP that is able to locally activate
the Arp2/3 complex to stimulate polymerization of actin beneath
the extracellular virus [12,18,19,20,21,22]. The polymerization of
actin beneath the virus particle provides a driving force that helps
to enhance the cell-to-cell spread of the virus [3,6,9,23,24].
In the absence of cell lysis, newly assembled vaccinia virions are
largely only released from the infected cell, when IEV fuse with the
plasma membrane. However, to reach the plasma membrane the
IEV first have to traverse the cortical actin cytoskeleton, which
consists of an extremely dense arrangement of actin filaments
beneath the plasma membrane. This dense actin cortex represents
a significant physical barrier to IEV, given their large size [25].
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8506Vesicles and secretory granules also face a similar problem during
exocytosis [26,27]. A variety of studies have shown that the
remodelling of cortical actin as well as active actin polymerization
plays an essential role in facilitating exocytosis [26,27]. It is
therefore not surprising given their size, that the release of IEV
from infected cells is also dependent on the assembly and
organization of the cortical actin cytoskeleton [11]. In addition,
vaccinia appears to enhance its release from infected cells in
culture by modulating the cortical actin by inhibiting RhoA
signalling to mDia, a key regulator of actin polymerization [11].
The virus achieves this by encoding F11, a protein that mimicks
ROCK to interact with RhoA to inhibit its downstream signalling
[28,29]. F11-mediated inhibition of RhoA signalling is also
responsible for stimulating virus-induced cell migration, which
may also help to enhance the spread of infection [28,30]. Our
previous observations on the role of F11 in promoting viral release
are based on the effects of over expressing dominant negative and
activated RhoA and mDia clones coupled with pharmalogical
approaches to modulate RhoA-mDia signalling and the actin
cytoskeleton. To extend these observations and directly investigate
whether that F11-mediated inhibition of RhoA signalling
promotes viral release and spread we have generated recombinant
viruses lacking F11 or expressing an F11 mutant (F11-VK), which
is deficient in binding RhoA [28]. We found that loss of F11 or its
ability to bind RhoA significantly reduces the release of infectious
virus from infected cells. Live cell imaging reveals that there was a
corresponding reduction in the rate of the spread of infection in
cell monolayers in culture. We also found that the ability of F11 to
bind RhoA also enhances viral spread in vivo in an intranasal
mouse model of infection.
Results
F11 Binds RhoA to Inhibit Its Signalling during Infection
Consistent with previous observations, immunofluorescence
analysis reveals that infection with the Western Reserve (WR)
strain of vaccinia results in the loss of actin stress fibres in addition
to the formation of numerous virus tipped actin tails (Fig. 1)
[28,31]. The loss of actin stress fibres is not due to the formation of
virus tipped actin tails as cells infected with the WR-A36R-YdF
virus, which is deficient in actin tail formation [7], also loose their
actin stress fibres (Fig. 1). In contrast, HeLa cells infected with the
recombinant DF11L virus, which does not express F11 (Fig. 2A),
have significantly more actin stress fibres than those infected with
WR or A36R-YdF at 8 hours post-infection (Fig. 1). The presence
of more actin stress fibres suggests that the level of RhoA signalling
is higher in DF11L as compared to WR infected cells. Quantitative
western blot analysis of Rhotekin-pull-down assays on infected cell
extracts confirmed that the level of GTP-bound RhoA is
significantly higher in DF11L than WR infected cells at 8 hours
post infection (Fig. 2B). These results using a recombinant virus is
consistent with our previous observations using RNAi mediated
ablation of F11 expression during infection [28,29]. Consistent
with its ability to inhibit RhoA signalling by mimicking the Rho
binding motif of ROCK [28], we found that F11 interacted
specifically with GTP (GTPcS) but not GDP bound GFP-RhoA
(Fig. 2C). This contrasts our previous observations which showed
F11 can bind both V14 (active GTP mimick) and N19 (inactive
GDP mimick) RhoA mutants [28].
To confirm that the loss of actin stress fibres observed during
WR infection are due to the loss of a direct interaction between
F11 and RhoA rather than the consequence of indirect signalling
effects, we generated a recombinant virus expressing a mutant
version of the protein (F11-VK), which is unable to bind RhoA
(Fig. 2D, E) [28]. Western blot analysis of infected cells reveals that
F11-VK is expressed at a similar time and level as the wild type
protein (Fig. 2A). Infection with the F11-VK virus, however, did
not result in a reduction in the level of GTP-bound RhoA at
8 hours post infection as seen with WR (Fig. 2B). Moreover, the
level of GTP-bound RhoA in F11-VK infected cells is similar to
that observed during DF11L infections (Fig. 2B). Consistent with
this, we observed that F11-VK infected cells also had prominient
actin stress fibres at 8 hours post infection (Fig. 1). Our
observations demonstrate that the direct binding of F11 to GTP
bound RhoA and subsequent inhibition of its down stream
signalling is required for the remodelling of the actin cytoskeleton
observed during vaccinia infection.
F11-Mediated Loss of RhoA Signalling Enhances the
Cell-to-Cell Spread of Vaccinia
We observed that the DF11L and F11-VK viruses were still
capable of inducing the formation of actin tails. However, it was
noticeable that cells infected with the DF11L and F11-VK viruses
had significantly fewer actin tails than those infected with WR
(Figs. 1, 3A). This similar reduction in the number of actin tails
could be due to defects in virus replication and assembly.
However, F11 is not required for virus replication and assembly
[30,32]. An alternative explanation for the reduction in number of
actin tails is that the inability of the DF11L and F11-VK viruses to
down regulate RhoA signalling impairs the ability of IEV particles
to reach and fuse with the plasma membrane. In agreement with
this, we found that there is a significant reduction in the
percentage of infectious virus particles released into the media
from cells infected DF11L and F11-VK viruses as compared to
WR (Fig. 3A). These data, which agree with our previous
observations using RNAi and over expression approaches in WR
infected cells[11], suggest that F11-mediated inhibition of RhoA is
likely to play an important role in the cell-to-cell spread of
vaccinia.
To directly examine if this is the case, we imaged the spread of
WR, DF11L and F11-VK viruses expressing YFP-A3, an
abundant viral core protein, in confluent monolayers of BS-C-1
cells during plaque formation. The cell monolayer was imaged for
48 hours immediately following the detection of YFP-A3 expres-
sion in the perinuclear region of a single infected cell ,8 hours
post infection (Fig. 3B, Movies S1, S2, S3). To quantify the rate of
cell-to-cell spread of each virus, we measured the area of YFP-A3
positive cells over time. In all three cases, after an initial delay,
corresponding to ,10 hours there was a linear increase in the size
of the developing plaque (Fig. 3C). The loss of F11 or its ability to
interact with RhoA both resulted in a similar dramatic reduction
in the rate at which the virus was able to spread as compared to
WR (Fig. 3B, C, Movies S1, S2, S3).
During the spread of WR the integrity of the cell monolayer was
disrupted due to the loss of cell-cell adhesion and migration of cells
away from the centre of the plaque (Figs. 3B, 4, Movies S4, S5,
S6). It was also noticeable that during the spread of WR there is a
prominent ‘‘wave front’’ in the phase image near the edge of the
developing plaque (Fig. 3B, Movie S1). Closer examination reveals
that this ‘‘wave front’’ corresponds to a combination of cells
undergoing migration and contracting ,2–3 hours before YFP-
A3 is detected (Fig. 4, Movie S4). In contrast, although there is
some loss of cell-cell adhesion at the initial site of infection, DF11L
infected cells did not contract or undergo any appreciable cell
migration (Figs. 3B, 4, Movies S2, S5). F11-VK infected cells also
did not contract when infected (Figs. 3B and 4, Movies S3, S6).
They did however loose some cell-cell adhesion and migrate, albeit
to a much lesser degree than WR infected cells (Figs. 3B and 4,
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PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8506Figure 1. F11 promotes loss of actin stress fibres during infection. (A) Representative images of infected HeLa cells stained with the viral
markers A27 and B5 reveals that loss of F11or its ability to bind RhoA (F11-VK) does not affect virus particle assembly (white arrow heads in inserts).
The presence of actin stress fibres (large white arrows) in DF11L and F11-VK but not WR or A36R-YdF infected cells is indicative of active RhoA
signalling. Scale bar=10 mm.
doi:10.1371/journal.pone.0008506.g001
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PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8506Figure 2. F11 binds GTP-bound RhoA to inhibit its signalling during infection. (A) Immunoblot analysis reveals that F11 is detected as early
as 2 hours post infection in WR and F11-VK but not DF11L infected cells. The kinetics of A36 and F12 expression are unaffected by the loss of F11 and
Nck represents a loading control. (B) Quantitative immunoblot analysis of Rho activation Rhotekin pull down assays reveals that WR but not DF11L or
F11-VK reduces the level of GTP-bound RhoA at 8 hours post infection as compared to non-infected controls. A representative immunoblot of the
level of GTP-bound and total RhoA is shown. Error bars represent standard error of the mean (SEM) from 4 independent experiments and *=P,0.05.
(C) Immunoblot analysis of glutathione resin pull down assays from vaccinia virus infected cell extracts, reveals that GST-tagged F11 interacts with
GTPcS (GTP) but not GDP bound RhoA. (D) Sequence alignment of F11 and the RhoA binding motif in ROCK1. Identical residues are shown in red and
the positions of valine 305 and lysine 307 in F11 that are mutated to alanine in the F11-VK mutant are indicated. (E) Immunoblot analysis of
glutathione resin pull down assays reveals that GST-tagged F11 but not F11-VK interacts with GFP-RhoA. Neither protein interacts with GFP-Rac. (D).
doi:10.1371/journal.pone.0008506.g002
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PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8506Figure 3. F11 enhances the cell-to-cell spread of vaccinia virus. (A) Quantitative analysis reveals that DF11L or F11-VK produce significantly
less actin tails than WR at 8 hours post infection. A lack of inhibition of RhoA signalling also results in a ,2.5 fold reduction in the % of infectious virus
released into the media from DF11L or F11-VK as compared to WR infected cells. Error bars represent SEM from 4 independent experiments and **
indicates P,0.01 and *** indicates P,0.001. (B) Phase contrast and fluorescence movie stills of a developing plaque at the indicated time reveals that
WR spreads faster in a monolayer of BS-C-1 cells than the DF11L or F11-VK viruses (Movies S1, S2, S3). The central clearing seen in WR and F11-VK
plaques is due to a loss of cell-cell adhesion and viral induced cell migration. (C) Quantitative analysis of the rate of spread of the indicated virus
during 48 hours. Error bars indicate SEM from 6 independent plaques.
doi:10.1371/journal.pone.0008506.g003
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PLoS ONE | www.plosone.org 5 December 2009 | Volume 4 | Issue 12 | e8506Movies S3, S6). The differences in cell adhesion and migration
between DF11L and F11-VK infected cells do appear to affect
viral spread as plaques formed by the F11-VK virus were larger
than those formed DF11L at four days post infection (Fig. 5A, B).
Plaques formed F11-VK were however still significantly
smaller than that observed for WR at four days post infection
(Fig. 5A, B).
F11-Mediated Inhibition of RhoA Enhances Spread of
Vaccinia In Vivo
Our observations in confluent cell monolayers in culture indicate
that F11 and its abililty to bind RhoA to inhibit its downstream
signalling enhances the cell-to-cell spread of infection. To explore
whether F11-mediated inhibition of RhoA signalling actually
contributes to the pathogenesis of vaccinia virus in vivo,w ei n f e c t e d
Figure 4. F11 promotes migration of infected cells. (A) Phase contrast and fluorescence movie stills at the indicated time of the leading edge
of a developing plaque induced by WR expressing YFP-A3L. Yellow arrowheads highlight infected cells migrating away from the initial infected cell
(open white arrowhead). Red arrowheads indicate cells that contract at the plaque front prior to moving (Movies S4, S5, S6).
doi:10.1371/journal.pone.0008506.g004
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PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8506C57BL6 mice intranasally with 5610
6 plaque-forming units of
purified WR, DF11L or F11-VK viruses. Intranasal innoculation of
WR results in an acute infection of the lung followed by subsequent
spread of extra-cellular virus to the visceral organs of the mouse [33].
To quantify the extent of virus spread in vivo we performed
plaque assays on trachea, lung and spleen extracts 1, 3 and 6 days
after intranasal inoculation. We found that high titres of WR were
detected in the trachea of animals one day post inoculation
Figure 5. Loss of F11 limits spread of infection in vitro and in vivo. (A) Representative images of plaques formed by WR, DF11L and F11-VK
at 4 days post infection. (B) Quantitative analysis of the size of plaques formed by WR, DF11L and F11-VK are shown as Box-and-whisker plots overlaid
with the data points (red). The boxes represent 25th and 75th percentile of the data, the line bisecting the box represents the median and ***
indicates P,0.001. (C) Quantitative analysis of viral titres in the trachea, lungs and spleens of WR (black bars), DF11L (white bars) or F11-VK (grey bars)
infected mice at 1, 3 and 6 days post inoculation. Error bars indicate SEM from five mice and the minimum limit of detection is 100 pfu/g tissue. (D)
Survival rates of C57/BL6 mice infected intra-nasally with 5610
6 pfu of WR, DF11L and F11-VK viruses (n=6).
doi:10.1371/journal.pone.0008506.g005
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subsequently to the spleen by day 6. In contrast, the DF11L virus
was mainly detected in the trachea at 3 days post inoculation and
similar levels of the virus still persisted in the tissue at day 6
(Fig. 5C). The DF11L virus was also impaired in its ability to
spread from the trachea, as low titres were detected in the lungs on
day 3 and it did not reach the spleen. Moreover, the titre of DF11L
in the lungs on day 3 was significantly lower compared to that of
WR. The F11-VK virus gave an intermediate phenotype between
WR and DF11L. F11-VK was detected in the trachea and lungs at
the same time as WR albeit at reduced titres (Fig. 5C). However, it
also persisted in the trachea as observed with DF11L. In contrast
to WR, F11-VK was also still present in the lungs at 6 days post
infection but was impaired in its ability to reach the spleen.
Consistent with its ability to spread and replicate, mice infected
with WR started dying at 4 days post-inoculation and had all died
by day 8 (Fig. 5D). In contrast, most of the DF11L infected mice still
survived at 8 days post infection (Fig. 5D). Animals infected with the
F11-VK virus initially survived longer than those infected with WR
but were also all dead by day 8. Taken together, our analysis reveals
that F11-mediated inhibitionof RhoA signalling acts to enhancethe
spread of infection not only in vitro but also in vivo.
Discussion
During recent years it has become clear from studies performed
in cell culture that viruses take advantage of the cytoskeleton of
their hosts to help faciliate their entry, replication and subsequent
spread [34,35,36,37,38]. This viral mediated exploitation of the
cytoskeleton often also involves manipulation of signalling
pathways involving Src and Abl kinases as well as RhoGTPases
[39,40]. In contrast to the situation in infected cells in culture, we
still understand very little concerning the role of the cytoskeleton
and its manipulation during viral spread and pathogenesis in vivo.
In the case of vaccinia virus, Gleevec mediated inhibition of Abl
and Arg tyrosine kinases reduces viral spread in vivo and also protects
mice from a lethal intranasal innoculation [14]. These in vivo
observations are consistent with data obtained from cells in culture
demonstrating that Abl family kinases are involved in vaccinia actin
tail formation and promoting the release of virus from the surface of
infected cells [14,15]. More recently, we found that F11-mediated
down regulation of RhoA signalling also promotes the release of virus
from infected cells in culture [11]. This conclusion was based on the
effects of over-expression of dominant negative and active RhoA and
mDia clones combined with pharmacological inhibition of RhoA
signalling and actin cytoskeleton dynamics. In our current study, we
directly examined whether inhibition of RhoA signalling promotes
viral release and spread using recombinant viruses lacking the F11L
gene or expressing an F11 mutant that is deficient in RhoA binding.
Our data now clearly demonstrates using an intranasal mouse model
of infection that F11-mediated inhibition of RhoA signalling
enhances the spread of vaccinia infection not only in cell monolayers
but also in vivo.
Consistent with previous publications using recombinant viruses
with nonsense mutations in the F11L gene [30,32], we found that
deletion of the majority of the F11L gene and loss of F11 expression
did not affect viral morphogenesis. The loss of F11 or its ability to
bind RhoA did however result in significantly higher levels of GTP
bound RhoA at 8 hours post infection, consistent with the presence
of actin stress fibres in DF11L or F11-VK as compared to WR or
WR-A36R-YdF infected cells. We also found that the increased
RhoA signalling resulted in a significant reduction in the number of
actin tails and amount of virus released into the culture medium.
This reduction must at least in part be responsible for the smaller
plaques formed by the DF11L and F11-VK viruses, as the ability to
induce actin tails is know to promote the formationof largerplaques
and enhance viral spread [3,9].
Although plaque size gives a measure of the efficiency of cell-to-cell
spread it provides no information concerning the dynamics of the
processasitrepresentsasinglefixed timepoint.Giventhisweimaged
viral spread in live cells during plaque formation to assess more
directly how F11-mediated inhibition of RhoA signalling enhances
the spread of infection. We found that F11 promotes the spread of
infection not only by enhancing viral release but by also stimulating
the migration of infected cells after their loss of cell-cell adhesion. Our
findings support and extend previous suggestions and observations in
isolated cells [11,28,30]. The loss of cell-cell adhesion during WR
infection is also consistent with the known role of RhoA signalling in
establishing and maintaining cell-cell contacts [41,42].
It was noticeable that cells within the monolayer contracted, even
though they are under agarose, a few hours after WR infection, as
previously observed in isolated infected cells in culture [31,43]. This
morphological change is dependent on F11, as well as its ability to
bind RhoA, as it was not observed in DF11L or F11-VK infected
cells. This suggests that virus induced cell rounding or contraction is
at least in part dependent on the modulation of RhoA signalling as
well as changes in cell adhesion and migration. Curiously, F11-VK
infected cells still exhibited some loss of cell-cell adhesion and limited
cell migration. These small changes cell-cell adhesion and cell
migration, rather than viral release, probably accounts for the
increased spread of F11-VK in vivo and larger plaques at 4 days post
infection when compared to DF11L, as both viruses induce similar
numbers of actin tails and also release similar amounts of infectious
virus particles in the media.
The similar rate of DF11L or F11-VK spread observed during
live cell imaging over the first 48 hours of infection would
however, suggest that viral release rather than cell migration
represents the main factor contributing to the intial spread of
infection. This hypothesis also agrees with the delayed spread of
F11-VK in vivo as compared to WR. Our data are also consistent
with the notion that it is the extra-cellular enveloped virus (EEV),
which is released from infected cells and resistant to complement
or antibody mediated neutralization, that is largely responsible for
the spread of infection throughout the mouse [44,45,46]. The
residual RhoA binding observed in our F11-VK pull downs may
account for the differences between DF11L and F11-VK viruses.
However, the similar levels of GTP-bound RhoA in DF11L or
F11-VK infected cells, would suggest that F11 has additional
functions beyond inhibition of RhoA. One attractive possibility is
that F11-VK interacts with additional RhoGTPases that are also
involved in regulation of cell-cell adhesion and cell migration.
Finally, recombinant poxviruses vectors currently represent
highly attractive delivery systems for vaccination against a variety
of infectious diseases as well as oncolytic agents against a wide
range of different cancers [47,48,49]. There is however still a need
to improve the safety, immunogenicity and/or oncolytic activity of
existing poxvirus based vectors if their full therapeutic potential in
the clinic is to be realized. The reduced viral spread, mortality and
the ability of mice to eliminate the DF11L virus from their lungs
suggests that deletion of the F11L gene in existing vaccinia vectors
may help to improve their safety and/or therapeutic potential as
oncolytic agents by limiting the spread of infection.
Materials and Methods
Construction of DF11L and F11-VK Recombinant Viruses
The F12L gene was amplified by PCR from Western Reserve
(WR) and cloned into the Not1/BamHI sites of pBS SKII
F11 Enhances Vaccinia Spread
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settes to generate F12L-pE/L-gpt and F12-pE/L-gpt-pE/L-
mCherry. The last 386 bp of the F11L gene, which contains the
promoter for F10L was cloned into the HindIII-SalI sites of F12L-
pE/L-gpt and F12-pE/L-gpt-pE/L-mCherry vectors to generate
the DF11L targeting vectors, F12L-pE/L-gpt-F11L (386 bp) and
F12-pE/L-gpt-pE/L-mCherry-F11L (386 bp). F12-pE/L-gpt-pE/
L-mCherry-F11L (386 bp) was transfected into cells infected with
the DF12L virus [50]. Fluorescence and gpt were used as selectable
markers to isolate a recombinant DF11L-mCherry virus by
successive rounds of plaque purification. Subsequently, DF11L-
mCherry virus infected cells were transfected with F12L-pE/L-
gpt-F11L (386 bp) and the DF11L virus lacking mCherry was
isolated by plaque purification. The F11-VK recombinant virus
was isolated by rescuing the DF11L virus using targeting vectors in
which the codons corresponding to valine 305 and lysine 307 of
the F11L gene were changed to encode alanines. Cells infected
with the DF11L and F11-VK viruses were subsequently transfect-
ed with the YFP-A3L targeting vector [11] and plaque purification
was used to isolate the fluorescent viruses DF11L-YFP-A3L and
F11-VK-YFP-A3L. The fidelity of all recombinant viruses was
confirmed by sequencing.
Infections, Immunofluorescence, and Antibodies
HeLa cells were infected and processed for immunofluorescence
or immunoblot analysis as described previously [29] using the
following antibodies: A27 (C3) [51], A36 [16], B5 (19C2) [52], F11
[28], F12 [10], GST polyclonal G-7781 (SIGMA-ALDRICH),
GFP monoclonal 3E1 (CR-UK), Nck polyclonal 06-288 (Milli-
pore) and RhoA monoclonal 26C4 (Santa Cruz Biotech, CA-
USA).
Quantification of Rho Activation, RhoA Pull Downs, and
Virus Production
Rho activation assays were performed on lysates from HeLa
cells infected for 8 hours as described previously [29]. The ratio of
activated:total RhoA was determined in 4 independent experi-
ments using Quantitative Westerns Methods on a Odyssey
Infrared Imaging System (LI-COR Corporate, NE). The data
for each virus is presented as the percentage of GTP bound Rho in
non-infected control cells.
Vaccinia virus infected HeLa cells expressing GFP-Rho
together with GST-F11 or GST were lyzed on ice in the Mg
2+
Rho lysis buffer (Upstate) containing 25 mM NaF, 20 mM PMSF,
20 mM orthovanadate and protease inhibitors. Cell lysates were
treated with 10 mM GDP or GTPcS for 30 minutes at 30uC after
addition of 10 mM EDTA. Subsequently, the treated cell lysates
were incubated with Glutathione sepharose 4B resin (Amersham)
and processed as previously described [53].
The number of new infectious virus particles produced during
infection was determined from triplicate plaque assays in four
independent experiments. The data is presented as the percentage
of the total infectious virus particles (intra-cellular, cell associated
and released) produced during infection at 8 hours that are
released into the media.
Live Cell Imaging
Images from live BS-C-1 cells infected with WR, DF11L or
F11L-VK viruses encoding YFP-A3L under agarose were
collected every 10 minutes for 48 hours using a CP-Achromat
5x Objective (Carl Zeiss, Germany) and CoolSnap HQ camera
(Photometrics, AZ) as described previously [29]. Quantification of
plaque size over time was determined from the area of the YFP-
A3L signal using MetaMorph (Molecular Devices Corporation,
CA).
Ethics Statement, Intranasal Inoculation, Virus Titration,
and Statistical Analysis
The mouse experiments were approved by the Ethical
Committee of Animal Experimentation (CEEA-CNB) of Centro
Nacional de Biotecnologia (CNB-CSIC) in accordance with
national and international guidelines and with the Royal Decree
(RD 1201/2005). Animals were housed in ventilated racks and
handled according to local and EU legal requirements. Two
groups of six C57/BL6 mice were inoculated intranasally with
5610
6 plaque forming units of WR, DF11L or F11-VK viruses in
20 ml phosphate-buffered saline. Mice were monitored daily for
survival. Inoculated animals were sacrificed at 1, 3 and 6 days
post-inoculation, the organs removed, homogenized and the levels
of infectious virus titrated as previously described [54]. Data are
presented as mean6standard error of the mean and were analyzed
by ANOVA or Student’s t test using Prism 4.0 (GraphPad
Software, CA). A P value of ,0.05 was considered statistically
significant.
Supporting Information
Movie S1 The movie shows the formation of a representative
plaque induced by Western Reserve virus encoding YFP-A3 over a
period of 48 hours (time stamp indicates hours and minutes) after
detection of the first infected cell. The right panel shows the signal
of YFP-A3, a core viral protein, which highlights the spread of
infection. The left panel phase image highlights the loss of cell-cell
adhesion and the strong ‘‘contraction wave’’ at the advancing
infection front.
Found at: doi:10.1371/journal.pone.0008506.s001 (8.72 MB
MOV)
Movie S2 The movie shows the formation of a representative
plaque induced by the DF11L virus encoding YFP-A3L over a
period of 48 hours (time stamp indicates hours and minutes) after
detection of the first infected cell. The right panel shows the signal
of YFP-A3, a core viral protein, which highlights the spread of
infection. The left panel phase image reveals that DF11L infected
cells do not detach from one another or undergo a strong
‘‘contraction wave’’ at the advancing infection front.
Found at: doi:10.1371/journal.pone.0008506.s002 (7.28 MB
MOV)
Movie S3 The movie shows the formation of a representative
plaque induced the F11-VK virus encoding YFP-A3L over a
period of 48 hours (time stamp indicates hours and minutes) after
detection of the first infected cell. The right panel shows the signal
of YFP-A3, a core viral protein, which highlights the spread of
infection. The left panel phase image reveals that F11-VK infected
cells, which do not contract, exhibit limited loss of cell-cell
adhesion and viral-induced cell migration.
Found at: doi:10.1371/journal.pone.0008506.s003 (6.51 MB
MOV)
Movie S4 The movie shows a close-up taken from Movie S1 of
the first 12 hours after detection of the first cell infected by
Western Reserve virus encoding YFP-A3 at the start of plaque
formation. The YFP-A3 signal highlights infected cells (right
panel). The phase image shows that cells in the center of the
plaque lose cell-cell adhesion, undergo contraction, and migrate
away from the initial site of infection (left panel).
Found at: doi:10.1371/journal.pone.0008506.s004 (1.54 MB
MOV)
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PLoS ONE | www.plosone.org 9 December 2009 | Volume 4 | Issue 12 | e8506Movie S5 The movie shows a close-up taken from Movie S2 of
the first 12 hours after detection of the first cell infected by the
DF11L virus encoding YFP-A3 at the start of plaque formation.
The YFP-A3 signal highlights infected cells (right panel). The
phase image shows that DF11L-infected cells maintain cell-cell
adhesion, and do not contact or migrate away from the initial site
of infection (left panel).
Found at: doi:10.1371/journal.pone.0008506.s005 (2.48 MB
MOV)
Movie S6 The movie shows a close-up taken from Movie S3 of
the first 12 hours after detection of the first cell infected by the
F11-VK virus encoding YFP-A3 at the start of plaque formation.
The YFP-A3 signal highlights infected cells (right panel). The
phase image shows that F11-VK infected cells, while not
contracting, exhibit limited loss of cell-cell adhesion and migration
(left panel).
Found at: doi:10.1371/journal.pone.0008506.s006 (2.22 MB
MOV)
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